证券研究报告 | 公司深度报告 2025 年 07 月 11 日 九号公司（689009.SH） 短交通为基、机器人为翼，成长为智慧生态级玩家 | 财务指标 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业收入（百万元） | 10,222 | 14,196 | 20,281 | 26,117 | 32,366 | | 增长率 yoy（%） | 1.0 | 38.9 | 42.9 | 28.8 | 23.9 | | 归母净利润（百万元） | 598 | 1,084 | 1,796 | 2,417 | 3,245 | | 增长率 yoy（%） | 32.5 | 81.3 | 65.7 | 34.6 | 34.3 | | ROE（%） | 10.8 | 17.4 | 22.4 | 23.2 | 23.7 | | EPS 最新摊薄（元） | 0.83 | 1.51 | 2.50 | 3.36 | 4.51 | | P/E（倍） | 69.8 | 38.5 | 23.2 | 17.3 | 12.9 | ...

证券研究报告 | 公司动态点评 2025 年 07 月 11 日 | 财务指标 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业收入（百万元） | 3,874 | 4,260 | 5,277 | 6,470 | 7,499 | | 增长率 yoy（%） | 3.3 | 10.0 | 23.9 | 22.6 | 15.9 | | 归母净利润（百万元） | 97 | 213 | 383 | 468 | 560 | | 增长率 yoy（%） | 42.7 | 119.6 | 80.0 | 22.1 | 19.7 | | ROE（%） | 3.5 | 7.3 | 11.8 | 12.7 | 13.3 | | EPS 最新摊薄（元） | 0.13 | 0.29 | 0.52 | 0.63 | 0.76 | | P/E（倍） | 84.8 | 38.6 | 21.5 | 17.6 | 14.7 | | P/B（倍） | 3.0 | 2.8 | 2.5 | 2.2 | 2.0 | 亚太股份（002284. ...

证券研究报告 | 公司动态点评 2025 年 07 月 11 日 工业富联（601138.SH） 归母净利润增速亮眼，AI 服务器云计算持续放量 | 财务指标 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业收入（百万元） | 476,340 | 609,135 | 773,193 | 952,747 | 1,155,064 | | 增长率 yoy（%） | -6.9 | 27.9 | 26.9 | 23.2 | 21.2 | | 归母净利润（百万元） | 21,040 | 23,216 | 30,785 | 35,310 | 41,622 | | 增长率 yoy（%） | 4.8 | 10.3 | 32.6 | 14.7 | 17.9 | | ROE（%） | 14.9 | 15.2 | 18.0 | 18.1 | 18.5 | | EPS 最新摊薄（元） | 1.06 | 1.17 | 1.55 | 1.78 | 2.10 | | P/E（倍） | 25.1 | 22.8 | 17.2 ...

Investment Rating - The investment rating for the company is "Buy" [6][19]. Core Views - The company is expected to achieve significant revenue growth, with projected revenues of 2,939 million yuan in 2025, representing a year-over-year growth of 14% [3][10]. - The net profit attributable to the parent company is forecasted to reach 687 million yuan in 2025, reflecting a year-over-year increase of 35.3% [3][10]. - The company is focusing on enhancing its market presence and product offerings, particularly in the OTC segment, which has seen a revenue increase of 64% year-on-year [5][10]. Financial Summary - Revenue projections for the company are as follows: - 2023: 1,942 million yuan - 2024: 2,578 million yuan (growth rate: 32.7%) - 2025: 2,939 million yuan (growth rate: 14.0%) - 2026: 3,568 million yuan (growth rate: 21.4%) - 2027: 4,243 million yuan (growth rate: 18.9%) [3][11]. - Net profit attributable to the parent company is projected as: - 2023: 383 million yuan - 2024: 508 million yuan (growth rate: 32.6%) - 2025: 687 million yuan (growth rate: 35.3%) - 2026: 902 million yuan (growth rate: 31.4%) - 2027: 1,106 million yuan (growth rate: 22.5%) [3][11]. - Key financial ratios include: - Return on Equity (ROE) is expected to increase from 14.1% in 2023 to 27.1% in 2027 [3][11]. - Earnings Per Share (EPS) is projected to rise from 0.55 yuan in 2023 to 1.58 yuan in 2027 [3][11]. Strategic Developments - The company has signed a collaboration agreement with Zhejiang University to establish a joint research center, investing a total of 20 million yuan [2][4]. - The focus on AI and traditional medicine aims to enhance product development and market competitiveness, particularly in the health and wellness sector [4][10]. Market Positioning - The company is enhancing its OTC product matrix and has implemented various strategies to improve sales efficiency and market penetration [5][10]. - The core products, including Wuling Capsules and Lingze Tablets, are positioned as essential items in the national basic drug catalog, indicating strong market demand and growth potential [10].

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected stock price increase of over 15% relative to the industry index in the next six months [5][18]. Core Views - The company is experiencing a performance recovery that exceeds expectations, with growth potential still present in the mid-term [1]. - The recovery in the cottonseed business is a significant factor contributing to the strong performance in the first half of the year, supported by favorable market conditions [2]. - The company is positioned as a leader in the plant extract sector, with stable profitability from key products and a strategic plan that is progressing steadily [9]. Financial Summary - **Revenue Forecast**: The company expects to achieve revenues of 6,872 million yuan in 2023, with a growth rate of 9.1%. Projections for 2024 and 2025 show revenues of 6,994 million yuan and 7,064 million yuan, respectively, with growth rates of 1.8% and 1.0% [1]. - **Net Profit**: The forecasted net profit for 2023 is 480 million yuan, with a year-on-year growth of 10.5%. However, a significant drop is expected in 2024, with a projected net profit of 94 million yuan, reflecting an 80.4% decline. A recovery is anticipated in 2025, with a net profit of 346 million yuan, representing a growth of 268.1% [1]. - **Earnings Per Share (EPS)**: The latest diluted EPS is projected to be 0.99 yuan in 2023, dropping to 0.19 yuan in 2024, and recovering to 0.72 yuan in 2025 [1][9]. - **Price-to-Earnings (P/E) Ratio**: The P/E ratio is expected to be 13.7 in 2023, soaring to 70.0 in 2024, and then stabilizing at 19.0 in 2025 [1][9]. Market Conditions - The cottonseed market is showing a stable upward trend, which has positively impacted the company's performance in the first half of the year [2]. - The company is expected to benefit from multiple growth drivers, including increased product volume, improved efficiency in overseas plantations, and a growing demand for health products [2].

Group 1: CPI Analysis - In June 2025, the CPI showed a marginal improvement with a year-on-year increase of 0.1%, reversing four months of negative growth[2] - The month-on-month CPI decline narrowed from -0.2% in May to -0.1% in June, slightly above the average decline of -0.18% from 2020 to 2024[2] - Core CPI rose to 0.7%, marking a 0.1 percentage point increase from the previous month, the highest in nearly 14 months[2] Group 2: PPI Analysis - The PPI in June 2025 decreased by 3.6% year-on-year, with the decline widening by 0.3 percentage points compared to May, marking four consecutive months of increasing decline[2] - Month-on-month, the PPI remained at -0.4%, indicating persistent downward pressure on industrial prices[2] - Factors contributing to PPI decline include abundant supply in domestic raw material manufacturing, seasonal price decreases, and reduced demand for thermal coal due to increased green energy[2] Group 3: Economic Outlook - Despite a slight rebound in CPI, consumer demand remains weak, and PPI continues to face downward pressure due to supply-demand imbalances and intensified competition among enterprises[3] - The central government's recent emphasis on regulating low-price competition may help improve supply-demand structures and provide some support for future price stability[3] - Risks include potential underperformance of domestic macroeconomic policies, unexpected interest rate changes, and concentrated credit events that could impact CPI and PPI forecasts[4]

证券研究报告 | 行业周报 2025 年 07 月 09 日 通信 算力催生数据中心向智算发展，推动 PCB 向高阶升级迭代，看好相 关产业链投资机会 | 股票 | 股票 | 投资 | EPS （元） | | PE | | | --- | --- | --- | --- | --- | --- | --- | | 代码 | 名称 | 评级 | 2025E | 2026E | 2025E | 2026E | | 002881.SZ | 美格智能 | 买入 | 0.73 | 0.92 | 61.56 | 48.85 | | 301285.SZ | 鸿日达 | 买入 | 0.21 | 0.7 | 161.9 | 48.57 | | 600941.SH | 中国移动 | 买入 | 6.77 | 7.17 | 16.54 | 15.61 | | 601728.SH | 中国电信 | 买入 | 0.38 | 0.4 | 20.08 | 19.08 | 资料来源：长城证券产业金融研究院 本周策略观点： OpenA I向甲骨文租赁数据中心算力，看好未来 AIDC 产业链投资机会。据 据《金融时报》和彭博社援引知情人士报道，O ...

证券研究报告 | 行业周报 2025 年 07 月 09 日 电力设备及新能源 PEM、AEM 电解槽技术有所突破，多地发布推动氢能发展政策 行情回顾：截至 2025 年 7 月 4 日，氢能源指数收盘价为 2135.09 点，本 周涨跌幅为 1.03%，2025 年初至今涨跌幅为 20.16%。氢能行业周涨幅前 五的公司为雪迪龙、凯美特气、盛德鑫泰、中材科技、华光环能，涨幅分 别为 31.74%、27.46%、22.40%、20.71%、20.06%；氢能行业周跌幅前 三的公司为光智科技、泰和科技、新迅达，跌幅分别为-15.82%、-9.40%、 -9.13%。 重点事件点评：内蒙古 12 套 1000Nm³/h 碱槽氢储项目获备案；全国首条 跨省绿氢管道内蒙古段获批；东莞首批氢能两轮车投运；摩洛哥大型绿色 氢能项目最新进展；英特利制氢电源保障 ACWA 乌兹别克斯坦绿氢工厂产 氢成功；乌兹别克斯坦塔什干绿氢项目成功实现产氢；广州启动氢车与加 氢站全面接入市新能源智能汽车监测平台工作；四川推动氢能"制储运用" 一体化，引领商业化新进程；六部委发展新能源清洁能源船舶，推动氢燃 料电池动力技术应用；明阳氢能新一 ...

证券研究报告 | 行业动态点评 2025 年 07 月 09 日 电力设备及新能源 美国大漂亮法案正式通过，或持续扩大中美新能源车产业发展差距 事件： 7 月 4 日,美国大漂亮法案（The "big beautiful" bill）正式通过，该法 案有多项条款对前任政府的通胀削减法案（IRA）支持新能源产业发展的内容 进行了多项修改及取消，料将对正处于转型发展期的美国新能源行业造成较 大的负面影响，或持续扩大中美之间差距。 强于大市 新能源车税收抵免即将全面取消，美国动力电池前沿技术商业化发展受限。 美国本土锂电行业公司如 Quantum Scape 和 Solid Power 在固态电池先进技 术方面具备较强优势,在原有 IRA 政策激励下，该类以技术为导向的小而美的 锂电企业配合美国本土车企新能源车装机应用的商业前景本较为光明。然而， 若美国市场失去新能源车新车购车退税激励（最高 7500 美元）及 4000 美元 的二手车购车退税激励，消费者未来对于选择新能源车优于燃油车的热情将 在相当程度上消退。除此之外，固态电池尚处于商业化早期阶段，尚未大规 模生产，故成本较高，最终将导致装载固态电池的车型售价较 ...

Investment Rating - The report maintains a rating of "Accumulate" for the company [4] Core Views - The company has achieved continuous revenue and profit growth for five consecutive years, demonstrating strong operational resilience and sustainable business model [2][3] - The acquisition of Yingu Pharmaceutical allows the company to enter the high-barrier nasal spray market, with significant growth potential anticipated from the core product, phenylquinhydramine nasal spray [2] - The company is expected to benefit from the aging population in China, leading to an expansion in the orthopedic medication market [8] Financial Performance Summary - Revenue is projected to grow from 3,311 million yuan in 2023 to 5,111 million yuan in 2027, with a compound annual growth rate (CAGR) of approximately 10.6% [1] - Net profit attributable to the parent company is expected to increase from 568 million yuan in 2023 to 1,099 million yuan in 2027, reflecting a CAGR of about 13.0% [1] - The company’s return on equity (ROE) is forecasted to remain strong, increasing from 20.3% in 2023 to 24.4% in 2027 [1] Growth Drivers - The company is focusing on channel expansion and differentiation to enhance loyalty and resource allocation in retail pharmacies [3] - The product matrix is diverse, with significant growth potential in core products, particularly in second-tier regions and grassroots medical institutions [3] - The company is embracing digitalization and AI to improve operational efficiency across various functions [3] Market Position - The company is recognized as a leading player in the domestic traditional Chinese medicine patch market, with a well-established brand and extensive product line [8] - The report highlights the company's ability to maintain a competitive edge through effective marketing integration and focus on core products [8]